Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
Immuneering (NASDAQ:IMRX) reported Q2 2025 financial results and significant clinical progress for its lead drug atebimetinib. The company highlighted exceptional 94% overall survival at 6 months in first-line pancreatic cancer patients (N=34) treated with atebimetinib plus modified Gemcitabine/nab-paclitaxel (mGnP), compared to 67% with standard care.
Key developments include a newly granted U.S. composition of matter patent extending exclusivity into 2042, and a notable case of a third-line pancreatic cancer patient maintaining partial response for over 18 months on atebimetinib monotherapy. The company reported Q2 2025 net loss of $14.4 million ($0.40 per share) and cash position of $26.4 million, with runway into 2026.
Immuneering plans to share updated survival data in Q3 2025 and has submitted an End of Phase 2 meeting request to FDA, with pivotal trial initiation expected in 2026.
Immuneering (NASDAQ:IMRX) ha comunicato i risultati finanziari del Q2 2025 e significativi progressi clinici per il suo farmaco di punta atebimetinib. L'azienda ha evidenziato una sopravvivenza globale eccezionale del 94% a 6 mesi nei pazienti con cancro del pancreas in prima linea (N=34) trattati con atebimetinib in combinazione con Gemcitabina/nab鈥憄aclitaxel modificato (mGnP), a fronte del 67% osservato con la terapia standard.
Tra gli sviluppi principali figura la concessione di un brevetto statunitense sulla composizione della sostanza che estende l'esclusivit脿 fino al 2042, nonch茅 il caso notevole di un paziente in terza linea che ha mantenuto una risposta parziale per oltre 18 mesi con monoterapia a base di atebimetinib. L'azienda ha riportato una perdita netta nel Q2 2025 di 14,4 milioni di dollari (0,40 dollari per azione) e una posizione di cassa pari a 26,4 milioni di dollari, con liquidit脿 stimata fino al 2026.
Immuneering prevede di condividere dati aggiornati sulla sopravvivenza nel Q3 2025 e ha presentato alla FDA una richiesta di End of Phase 2 meeting; l'avvio dello studio pivotale 猫 atteso nel 2026.
Immuneering (NASDAQ:IMRX) inform贸 los resultados financieros del 2T 2025 y avances cl铆nicos significativos para su f谩rmaco principal atebimetinib. La compa帽铆a destac贸 una supervivencia global excepcional del 94% a los 6 meses en pacientes con c谩ncer de p谩ncreas de primera l铆nea (N=34) tratados con atebimetinib m谩s Gemcitabina/nab鈥憄aclitaxel modificado (mGnP), frente al 67% con la atenci贸n est谩ndar.
Entre los hitos figura la concesi贸n de una patente estadounidense de composici贸n de la materia que extiende la exclusividad hasta 2042, y un caso notable de un paciente en tercera l铆nea que mantiene respuesta parcial por m谩s de 18 meses con monoterapia de atebimetinib. La compa帽铆a report贸 una p茅rdida neta en el 2T 2025 de $14.4 millones ($0.40 por acci贸n) y una posici贸n de efectivo de $26.4 millones, con liquidez prevista hasta 2026.
Immuneering planea compartir datos de supervivencia actualizados en el 3T 2025 y ha solicitado a la FDA una reuni贸n End of Phase 2; se espera iniciar el ensayo pivotal en 2026.
Immuneering (NASDAQ:IMRX)電� 2025雲� 2攵勱赴 鞛鞁れ爜瓿� 欤茧牓 頉勲炒 鞎诫 鞎勴厡牍勲⿺韹半嫏(atebimetinib)鞚� 欤检殧 鞛勳儊 歆勳爠鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 鞎勴厡牍勲⿺韹半嫏瓿� 氤�順� Gemcitabine/nab鈥憄aclitaxel(mGnP)鞚� 氤戩毄頃� 1彀� 旆岇灔鞎� 頇橃瀽(N=34)鞐愳劀 6臧滌洈 鞝勳泊 靸濎〈鞙澊 94%搿� 韮侅洈頃� 瓴瓣臣毳� 氤挫榾鞙茧┌, 鞚措姅 響滌 旃橂鞚� 67%鞕� 牍勱祼霅滊嫟瓿� 臧曥“頄堨姷雼堧嫟.
欤检殧 靹标臣搿滊姅 氚绊儉甓岇潉 2042雲勱箤歆� 鞐办灔頃橂姅 氙戈淡 氍检臁办劚(composition of matter) 韸鬼棃鞚� 鞁犼窚 霌彪瓿�, 3彀� 旃橂 頇橃瀽臧� 鞎勴厡牍勲⿺韹半嫏 雼弲鞖旊矔鞙茧 18臧滌洈 鞚挫儊 攵�攵勲皹鞚戩潉 鞙犾頃� 欤茧頃� 毵岉暅 靷臧� 韽暔霅╇媹雼�. 須岇偓電� 2025雲� 2攵勱赴 靾滌啇鞁� 1,440毵� 雼煬 (欤茧嫻 0.40雼煬)鞕� 順勱笀 鞛旉碃 2,640毵� 雼煬毳� 氤搓碃頄堨溂氅�, 鞛愱笀鞚� 2026雲勱箤歆� 鞙犾霅� 瓴冹溂搿� 氤挫瀰雼堧嫟.
Immuneering鞚� 2025雲� 3攵勱赴鞐� 鞐呺嵃鞚错姼霅� 靸濎〈 雿办澊韯� 瓿店皽毳� 瓿勴殟頃橁碃 鞛堨溂氅� FDA鞐� End of Phase 2 須岇潣 鞖旍箔鞚� 鞝滌稖頄堨溂氅�, 頂茧炒韮�(瓴办爼鞝�) 鞁滍棙 臧滌嫓電� 2026雲勳溂搿� 鞓堨儊霅╇媹雼�.
Immuneering (NASDAQ:IMRX) a publi茅 ses r茅sultats financiers du T2 2025 et des progr猫s cliniques significatifs pour son candidat principal atebimetinib. La soci茅t茅 a mis en 茅vidence un taux de survie globale exceptionnel de 94% 脿 6 mois chez des patients en premi猫re ligne atteints d'un cancer du pancr茅as (N=34) trait茅s par atebimetinib associ茅 脿 Gemcitabine/nab鈥憄aclitaxel modifi茅 (mGnP), contre 67% avec la prise en charge standard.
Parmi les avanc茅es figurent l'attribution r茅cente d'un brevet am茅ricain de composition de mati猫re prolongeant l'exclusivit茅 jusqu'en 2042, ainsi qu'un cas notable d'un patient en troisi猫me ligne maintenant une r茅ponse partielle depuis plus de 18 mois sous monoth茅rapie par atebimetinib. La soci茅t茅 a annonc茅 une perte nette au T2 2025 de 14,4 M$ (0,40$ par action) et une tr茅sorerie de 26,4 M$, avec une visibilit茅 de financement jusqu'en 2026.
Immuneering pr茅voit de diffuser des donn茅es de survie mises 脿 jour au T3 2025, a soumis une demande de r茅union End of Phase 2 aupr猫s de la FDA, et pr茅voit de lancer l'essai pivotal en 2026.
Immuneering (NASDAQ:IMRX) meldete die Finanzergebnisse f眉r Q2 2025 sowie bedeutende klinische Fortschritte f眉r sein Leitprodukt atebimetinib. Das Unternehmen hob eine au脽ergew枚hnliche 6鈥慚onats-Gesamt眉berlebensrate von 94% bei Erstlinien-Patienten mit Pankreaskarzinom (N=34) hervor, die mit atebimetinib plus modifiziertem Gemcitabin/nab鈥慞aclitaxel (mGnP) behandelt wurden, verglichen mit 67% unter Standardtherapie.
Wesentliche Entwicklungen umfassen die Erteilung eines neuen US-Patents zur Wirkstoffzusammensetzung, das die Exklusivit盲t bis 2042 verl盲ngert, sowie einen bemerkenswerten Fall eines Drittlinien-Patienten, der 眉ber 18 Monate eine partielle Remission unter Atebimetinib-Monotherapie aufrechterhielt. Das Unternehmen verzeichnete einen Nettoverlust im Q2 2025 von 14,4 Mio. USD (0,40 USD je Aktie) und eine Barposition von 26,4 Mio. USD, mit Finanzierungsreichweite bis 2026.
Immuneering plant, aktualisierte 脺berlebensdaten im Q3 2025 zu ver枚ffentlichen, hat ein End鈥憃f鈥慞hase鈥�2鈥慚eeting bei der FDA angefragt, und rechnet mit dem Start der pivotalen Studie im Jahr 2026.
- Exceptional 94% overall survival at 6 months in first-line pancreatic cancer trial vs 67% for standard care
- New U.S. composition of matter patent granted, providing exclusivity into 2042
- Third-line pancreatic cancer patient showing 34% tumor reduction and 96% CA 19-9 reduction after 18 months
- Reduced R&D expenses from $10.7M to $10.5M year-over-year
- Net loss increased to $14.4M from $14.1M year-over-year
- Cash position decreased to $26.4M from $36.1M in six months
- Pivotal trial initiation not expected until 2026
Insights
Impressive 94% 6-month survival rate in pancreatic cancer trial shows remarkable potential compared to 67% standard-of-care benchmark.
The 94% overall survival rate at 6 months for first-line pancreatic cancer patients treated with atebimetinib plus modified Gemcitabine/nab-paclitaxel (mGnP) represents a potentially significant advance in a notoriously difficult-to-treat cancer. For context, the standard-of-care GnP regimen achieved only 67% survival at the same timepoint in its pivotal study, with rapid decline to 50% by 8.5 months. This 27 percentage point improvement is particularly noteworthy in pancreatic cancer, where treatment advances have been incremental at best.
The Phase 2a trial data (n=34) showing 72% progression-free survival at 6 months with median OS and PFS not yet reached suggests durability of response. The favorable tolerability profile is equally important, as pancreatic cancer patients often struggle with treatment-related side effects that compromise quality of life.
The case study of a third-line pancreatic cancer patient maintaining a partial response on atebimetinib monotherapy for over 18 months is exceptional. This patient, who progressed through both FOLFIRINOX and Gem/Cis/nab-Pac, demonstrated a 34% reduction in target lesions and 96% reduction in CA 19-9 levels (a tumor marker). The reported weight gain of ~16% suggests the treatment is well-tolerated and potentially improving overall patient health.
The upcoming updated OS and PFS data in Q3 2025 will be critical to validate these early positive signals, particularly whether the survival curve maintains its advantage beyond the 6-month mark. The FDA's feedback on pivotal study plans will shape the company's path to potential approval in this high-unmet-need indication.
Newly granted composition of matter patent extending to 2042 significantly enhances atebimetinib's commercial value and partnership potential.
The USPTO's grant of a composition of matter patent for atebimetinib marks a crucial intellectual property milestone for Immuneering. This patent, expected to provide exclusivity until 2042 with potential for further extension, substantially strengthens the company's market position and commercial prospects.
Composition of matter patents are the strongest form of pharmaceutical IP protection, covering the drug molecule itself rather than just applications or formulations. This patent is particularly significant as it's the first granted in the U.S. for a "deep cyclic inhibitor" - establishing Immuneering as a pioneer in this drug class designed to overcome cancer resistance mechanisms.
The company's disclosure of additional pending patent applications extending potentially to 2044 suggests a comprehensive IP strategy covering compounds, pharmaceutical compositions, and methods of use. This layered approach to patent protection can effectively block competitors and create a formidable barrier to generic entry.
For potential pharmaceutical partners evaluating atebimetinib, this robust patent position significantly enhances the drug's attractiveness for licensing or acquisition, particularly given the promising clinical data in pancreatic cancer. The extended exclusivity period provides ample time for commercial exploitation across multiple potential indications, maximizing the drug's revenue potential before generic competition.
This patent grant comes at a strategic time as Immuneering prepares for pivotal trials and likely partnership discussions, substantially strengthening their negotiating position with both potential partners and investors.
- Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance听-
- Exceptional
- Newly issued U.S. composition of matter patent for atebimetinib expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension -
- Request for End of Phase 2 meeting has been submitted to the FDA;
pivotal trial expected to initiate in 2026 -
CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today reported financial results for the second quarter ended June 30, 2025, and provided several business updates.
鈥淲e are excited to announce updated OS and PFS data from our ongoing Phase 2a trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients in the coming weeks. Last quarter we reported an exceptional
鈥淲e are busy preparing for our Phase 3 pivotal trial, and have now submitted our end of phase 2 meeting request to FDA. In addition, the granting of our composition of matter patent for atebimetinib by the United States Patent and Trademark Office (USPTO) was an important milestone for our company. We expect the long patent runway we are forging for atebimetinib will support our efforts to maximize its therapeutic potential across multiple indications,鈥� Zeskind concluded.
Corporate Highlights
- Reported Positive Overall Survival Data for Atebimetinib from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients: In June, Immuneering shared exceptional data from its ongoing Phase 2a trial of atebimetinib in combination with modified mGnP in first-line pancreatic cancer. The company reported that
94% OS and72% PFS were observed at 6 months (n=34; patients treated at the 320 mg once-daily dose of atebimetinib), with median OS and PFS not yet reached. A markedly favorable tolerability profile was also observed. All results were reported using a data cutoff date of May 26, 2025. Subject to regulatory feedback, the company plans to initiate a pivotal trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients in 2026. - Granted U.S. Composition of Matter Patent for Atebimetinib:听In July, the company was granted a composition of matter patent for atebimetinib by the USPTO, which is expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension. The patent is the first granted in the U.S. for a deep cyclic inhibitor, a once-daily pill that aims to drive longer-lasting benefit by outpacing resistance mechanisms that cause cancer drugs to stop working. Additional patent applications for atebimetinib are pending, directed to compounds, pharmaceutical compositions, and methods of use, with expiration expected into 2044.
- Third-Line Pancreatic Cancer Patient Passes 18-month Mark on Atebimetinib Monotherapy: Today, Immuneering is providing an update on a pancreatic cancer patient in the third-line setting who has received atebimetinib monotherapy for more than 18 months as a participant in the company鈥檚 Phase 1 trial and who remains on treatment. The patient 鈥� who previously experienced disease progression on first-line FOLFIRINOX and second-line Gem/Cis/nab-Pac 鈥� has been on atebimetinib monotherapy at 240 mg once daily and has maintained a partial response, including a
34% reduction in target lesions (RECIST sum of longest diameters) for a confirmed partial response, and a96% reduction in peak CA 19-9 levels. Treatment continued to be well tolerated by the patient, with a ~16% weight gain observed.
Near-Term Milestone Expectations
Immuneering is planning for several near-term milestones related to atebimetinib, including to:
- Announce updated OS and PFS data from first-line pancreatic cancer patients (n = 34) treated with atebimetinib + mGnP in Q3 2025
- Receive regulatory feedback on pivotal study plans in Q4 2025
- Initiate pivotal, randomized trial of atebimetinib in combination with mGnP in first-line pancreatic cancer in 2026
- Initiate additional atebimetinib clinical trial combination arms in 2026
Second Quarter 2025 Financial Highlights
Cash Position: Cash and cash equivalents as of June听30, 2025 were
Research and Development (R&D) Expenses: R&D expenses for the quarter ended June 30, 2025 were
General and Administrative (G&A) Expenses: G&A expenses for the quarter ended June 30, 2025 were
Net Loss: Net loss attributable to common stockholders was
2025 Financial Guidance
- Based on cash and cash equivalents as of June 30, 2025, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into 2026.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company outpacing cancer to help patients outlive their disease. The Company鈥檚 lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily deep cyclic inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company鈥檚 development pipeline also includes early-stage programs. For more information, please visit .
Forward-Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: our plans to develop, manufacture and commercialize our product candidates; the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer, including modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer; the treatment potential of our pipeline product candidates in other types of cancer; the plans and objectives of Company management for future operations, including with respect to the timing, planning, enrollment and execution of additional atebimetinib combination trials and a potential pivotal trial of atebimetinib in combination with mGnP; the timing for release of additional results from the Phase 2a portion of the atebimetinib trial; the timing and substance of regulatory feedback on pivotal trial plans; expectations regarding our cash runway; the expected expiration of our issued and pending patents and additional planned patent applications, including the U.S. composition of matter patent covering atebimetinib; our ability to obtain patent term extension on our U.S. composition of matter patent; and our expectations for a long patent runway we are forging for atebimetinib will support our efforts to maximize its full therapeutic potential, extending to many different cancer types and combinations.
These forward-looking statements are based on management鈥檚 current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding and ability to continue as a going concern; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption 鈥淩isk Factors鈥� in our Quarterly Report on Form 10-Q for the three months ended June 30, 2025, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Media Contact:
Gina Nugent
Investor Contact:
Laurence Watts
619-916-7620
| IMMUNEERING CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) | ||||||||||||
| 听 | ||||||||||||
| 听 | Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||
| 听 | 听 | 2025 | 听 | 听 | 2024 | 听 | 听 | 2025 | 听 | 听 | 2024 | 听 |
| Operating expenses | 听 | 听 | 听 | 听 | ||||||||
| Research and development | $ | 10,454,160 | 听 | $ | 10,651,958 | 听 | $ | 21,925,852 | 听 | $ | 21,854,372 | 听 |
| General and administrative | 听 | 4,296,417 | 听 | 听 | 4,254,473 | 听 | 听 | 8,302,059 | 听 | 听 | 8,370,493 | 听 |
| Amortization of intangible asset | 听 | 7,317 | 听 | 听 | 7,317 | 听 | 听 | 14,633 | 听 | 听 | 14,633 | 听 |
| Total operating expenses | 听 | 14,757,894 | 听 | 听 | 14,913,748 | 听 | 听 | 30,242,544 | 听 | 听 | 30,239,498 | 听 |
| Loss from operations | 听 | (14,757,894 | ) | 听 | (14,913,748 | ) | 听 | (30,242,544 | ) | 听 | (30,239,498 | ) |
| 听 | 听 | 听 | 听 | 听 | ||||||||
| Other income (expense) | 听 | 听 | 听 | 听 | ||||||||
| Interest income | 听 | 324,013 | 听 | 听 | 826,104 | 听 | 听 | 762,532 | 听 | 听 | 1,630,988 | 听 |
| Other income, net | 听 | - | 听 | 听 | 7,717 | 听 | 听 | - | 听 | 听 | 220,754 | 听 |
| Net loss | $ | (14,433,881 | ) | $ | (14,079,927 | ) | $ | (29,480,012 | ) | $ | (28,387,756 | ) |
| 听 | 听 | 听 | 听 | 听 | ||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.40 | ) | $ | (0.47 | ) | $ | (0.82 | ) | $ | (0.96 | ) |
| Weighted-average common shares outstanding, basic and diluted | 听 | 35,985,878 | 听 | 听 | 29,653,355 | 听 | 听 | 35,759,026 | 听 | 听 | 29,511,856 | 听 |
| 听 | 听 | 听 | 听 | 听 | ||||||||
| Other comprehensive loss: | 听 | 听 | 听 | 听 | ||||||||
| Unrealized loss from marketable securities | 听 | - | 听 | 听 | 1,084 | 听 | 听 | - | 听 | 听 | 778 | 听 |
| Comprehensive Loss | $ | (14,433,881 | ) | $ | (14,078,843 | ) | $ | (29,480,012 | ) | $ | (28,386,978 | ) |
| 听 | 听 | 听 | 听 | 听 | ||||||||
| IMMUNEERING CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) | |||||||
| 听 | |||||||
| 听 | June 30, 2025 | December 31, 2024 | 听 | ||||
| 听 | 听 | 听 | 听 | ||||
| Assets | 听 | 听 | 听 | ||||
| Current assets: | 听 | 听 | 听 | ||||
| Cash and cash equivalents | $ | 26,355,498 | 听 | $ | 36,144,720 | 听 | 听 |
| Prepaids and other current assets | 听 | 1,369,928 | 听 | 听 | 3,442,849 | 听 | 听 |
| Total current assets | 听 | 27,725,426 | 听 | 听 | 39,587,569 | 听 | 听 |
| 听 | 听 | 听 | 听 | ||||
| Property and equipment, net | 听 | 964,138 | 听 | 听 | 1,122,865 | 听 | 听 |
| Goodwill | 听 | 6,690,431 | 听 | 听 | 6,690,431 | 听 | 听 |
| Intangible asset, net | 听 | 335,780 | 听 | 听 | 350,413 | 听 | 听 |
| Right-of-use assets, net | 听 | 3,498,967 | 听 | 听 | 3,667,352 | 听 | 听 |
| Other assets | 听 | 841,726 | 听 | 听 | 1,295,783 | 听 | 听 |
| Total assets | $ | 40,056,468 | 听 | $ | 52,714,413 | 听 | 听 |
| 听 | 听 | 听 | 听 | ||||
| Liabilities and Stockholders' Equity | 听 | 听 | 听 | ||||
| Current liabilities: | 听 | 听 | 听 | ||||
| Accounts payable | $ | 2,395,203 | 听 | $ | 1,958,536 | 听 | 听 |
| Accrued expenses | 听 | 4,514,960 | 听 | 听 | 4,973,129 | 听 | 听 |
| Other liabilities | 听 | 209,708 | 听 | 听 | 233,665 | 听 | 听 |
| Lease liabilities | 听 | 366,959 | 听 | 听 | 338,438 | 听 | 听 |
| Total current liabilities | 听 | 7,486,830 | 听 | 听 | 7,503,768 | 听 | 听 |
| 听 | 听 | 听 | 听 | ||||
| Long-term liabilities: | 听 | 听 | 听 | ||||
| Lease liabilities, net of current portion | 听 | 3,633,601 | 听 | 听 | 3,824,419 | 听 | 听 |
| Total liabilities | 听 | 11,120,431 | 听 | 听 | 11,328,187 | 听 | 听 |
| Commitments and contingencies | 听 | 听 | 听 | ||||
| Stockholders鈥� equity: | 听 | 听 | 听 | ||||
| Preferred stock, | 听 | - | 听 | 听 | - | 听 | 听 |
| Class A common stock, | 听 | 35,987 | 听 | 听 | 31,050 | 听 | 听 |
| Class B common stock, | 听 | - | 听 | 听 | - | 听 | 听 |
| Additional paid-in capital | 听 | 282,675,249 | 听 | 听 | 265,650,362 | 听 | 听 |
| Accumulated deficit | 听 | (253,775,199 | ) | 听 | (224,295,186 | ) | 听 |
| Total stockholders' equity | 听 | 28,936,037 | 听 | 听 | 41,386,226 | 听 | 听 |
| Total liabilities and stockholders' equity | $ | 40,056,468 | 听 | $ | 52,714,413 | 听 | 听 |
| 听 | 听 | 听 | 听 | ||||
FAQ
What were Immuneering's (IMRX) key clinical results for atebimetinib in pancreatic cancer?
What is the patent protection timeline for Immuneering's atebimetinib?
What was Immuneering's (IMRX) financial position in Q2 2025?
When will Immuneering (IMRX) start its pivotal trial for atebimetinib?
What were the results from the third-line pancreatic cancer patient on atebimetinib?
